Gary Yeung is a life science investor, executive, co-founder, board member and advisor with extensive experience forming and building biotech companies and developing novel therapies. He has raised over $600 million in capital and has co-founded three biotech startups and a venture capital firm: two spin-offs from Stanford University and Duke University, GGTG Biosciences and YK Bioventures Capital. Gary has also built multiple biotech companies: Xilis, NiKang, Erasca, Guardant Health and Annexon (NASDAQ: ERAS, GH and ANNX) as well as leading organizations engaged in filing 42 INDs and launching multiple FDA-approved treatments at Genentech. He is a former strategy consultant and operational leader at McKinsey and GE.